ArticleBeilstein journal of nanotechnology2025
Toward clinical translation of carbon nanomaterials in anticancer drug delivery: the need for standardisation.
Article in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.Archives of microbiology · 2026Review
- Nanocarbon as a Quantum Material for Biointerfaces and Magnetic Platforms in Theranostic Biomedicine in Oncology: A Critical Review.Biosensors · 2026Review
- Bridging solubility, stability, and translation: advances in carbon nanotube-based drug delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Carbon Dots in Nanomedicine: Advanced Fabrication, Biomedical Applications, and Future Clinical Perspectives.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbon nanomaterials (CNMs), including graphene, carbon nanotubes, and carbon dots, have attracted considerable interest as nanocarriers for drug delivery due to their unique physicochemical properties. Their high surface area, biocompatibility, and modifiable surface chemistry make them highly attractive for a range of biomedical applications. However, concerns regarding toxicity and regulatory hurdles remain major barriers to clinical translation. Current research is therefore focused on standardizing CNM synthesis and characterisation methods, minimizing toxicity, and facilitating regulatory approval. Despite these challenges, CNMs hold substantial promise for enhancing therapeutic delivery, particularly in areas such as cancer treatment. This perspective highlights critical considerations in the development of CNM-based nanocarriers, spanning from initial design to clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.